COVID-19 studies are our top priority. For all other trials, there is a 4-week delay in processing a trial submitted to the ANZCTR and additional delays for updates of registered trials. We appreciate your patience.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02588261




Registration number
NCT02588261
Ethics application status
Date submitted
26/10/2015
Date registered
27/10/2015
Date last updated
12/02/2019

Titles & IDs
Public title
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Scientific title
An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Secondary ID [1] 0 0
2015-002894-39
Secondary ID [2] 0 0
8273-CL-0302
Universal Trial Number (UTN)
Trial acronym
SOLAR
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-small Cell Lung Cancer (NSCLC) 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - naquotinib mesilate
Treatment: Drugs - Erlotinib
Treatment: Drugs - Gefitinib

Experimental: ASP8273 - Participants received 300 mg of ASP8273 orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).

Active Comparator: erlotinib or gefitinib - Participants received 150 mg of erlotinib or 250 mg of gefitinib orally once daily in 28-day cycles until one of the discontinuation criteria was met (developed radiological progressive disease, required to receive local or systemic anti-cancer treatment, developed unacceptable toxicity, participant pregnancy, investigator decision, required to receive significant surgical procedure, participant protocol deviation or noncompliance, participant decline of further treatment and participant lost to follow-up).


Treatment: Drugs: naquotinib mesilate
Participants received ASP8273 300 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day.

Treatment: Drugs: Erlotinib
Participants received erlotinib 150 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.

Treatment: Drugs: Gefitinib
Participants received gefitinib 250 mg was taken orally once daily with water, with or without food, at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS) as Assessed by Independent Radiologic Review (IRR) - PFS was defined as the time from the date of randomization until the date of radiological disease progression or until death due to any cause, based on the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as assessed by IRR. Results are based Kaplan-Meier estimate. If a participant had neither progressed nor died, who received any further anticancer therapy for the disease before radiological progression, the participant was censored at the date of last radiological assessment. If progression or death occurred after missing 2 scheduled radiological assessments, the participant was censored at the date of last radiological assessment or at the date of randomization if no post-baseline radiological assessment was available.
Timepoint [1] 0 0
From date of randomization up to data cut-off date 09 May 2017 (approximately 15 months)
Secondary outcome [1] 0 0
Percentage of Deaths - All events of death after the first study drug administration were included.
Timepoint [1] 0 0
From date of randomization up to data cut-off date 21 Dec 2017 (approximately 22 months)
Secondary outcome [2] 0 0
Percentage of Participants With Objective Response (OR) - Percentage of participants with OR was defined as the proportion of participants with best overall response as complete response (CR) or partial response (PR) without confirmation based on the RECIST v1.1 as assessed by the blinded IRR. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to < 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters.
Timepoint [2] 0 0
From date of first dose of study drug up to data cut-off date 09 May 2017 (approximately 15 months)
Secondary outcome [3] 0 0
PFS as Assessed by the Investigator - PFS was defined as the time from the date of randomization until the date of radiological disease progression or until death due to any cause, based on RECIST V1.1, as assessed by local investigator. Results are based Kaplan-Meier estimate. If a participant had neither progressed nor died, who received any further anticancer therapy for the disease before radiological progression, the participant was censored at the date of last radiological assessment. If progression or death occurred after missing 2 scheduled radiological assessments, the participant was censored at the date of last radiological assessment or at the date of randomization if no post-baseline radiological assessment was available.
Timepoint [3] 0 0
From date of randomization up to data cut-off date 09 May 2017 (approximately 15 months)
Secondary outcome [4] 0 0
Percentage of Participants With Disease Control - Percentage of participants with disease control was defined as the proportion of participants whose best overall response was rated as CR, PR or stable disease (SD) among all analyzed participants based on RECIST V1.1. CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to < 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters. SD was defined as neither sufficient decrease to qualify for PR nor sufficient increase to qualify for progressive disease taking as reference the smallest sum of diameters while on study drug.
Timepoint [4] 0 0
From date of first dose of study drug up to data cut-off date 09 May 2017 (approximately 15 months)
Secondary outcome [5] 0 0
Duration of Response (DOR) - DOR was defined as the time from the date of the first response CR/PR (whichever was first recorded) as assessed by IRR to the date of radiographical progression or date of censoring. If a participant had not progressed, the participant was censored at the date of last radiological assessment or at the date of first CR/PR if no post-baseline radiological assessment was available. Results are based Kaplan-Meier estimate.
Timepoint [5] 0 0
From date of first response up to data cut-off date 09 May 2017 (approximately 15 months)
Secondary outcome [6] 0 0
Number of Participants With Adverse Events (AEs) - Safety was assessed by AEs, which included abnormalities identified during a medical test (e.g. laboratory tests, vital signs, electrocardiogram, etc.) if the abnormality induced clinical signs or symptoms, needed active intervention, interruption or discontinuation of study medication or was clinically significant. A treatment-emergent AE (TEAE) was defined as an AE observed after starting administration of the study drug. AEs were considered serious (SAEs) if the AE resulted in death, was life threatening, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, resulted in congenital anomaly, or birth defect or required inpatient hospitalization or led to prolongation of hospitalization.
Timepoint [6] 0 0
From first dose of study drug up to 30 days after last dose of study drug taken up to data cut-off 09 May 2017
Secondary outcome [7] 0 0
Functional Assessment of Cancer Therapy - EGFR Inhibitors Subscale (FACT-EGFRI-18) Questionnaire - ACT-EGFRI-18 is an 18-item Likert-scaled questionnaire, used to assess the effect of EGFR inhibitors on quality of life (QoL). The questionnaire is arranged in three HRQL dimensions: physical (seven items), social/emotional (six items), and functional well-being (five items). The response scores ranged from 0 to 4, and the response categories include "not at all", "a little bit", "somewhat", "quite a bit", and "very much." Negatively worded items (e.g., "My skin bleeds easily "or "My skin condition affects my mood") are reverse-scored, so that participants who experience a higher impact of symptom burden on HRQL receive a lower score (range 0-72).
Timepoint [7] 0 0
Day 1 of each cycle up to data cut off 09 May 2017 (approximately 15 months)
Secondary outcome [8] 0 0
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 (EORTC-QLQ-LC13) - The EORTC-QLQ-LC13 is a validated module of the EORTC-QLQ-Core 30, which includes module items that evaluate symptoms such as cough, hemoptysis, shortness of breath, sore mouth or tongue, dysphagia, tingling hands or feet, hair loss and pain. The total score for the questionnaire ranges from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning whereas a high score for a symptom scale or item represents a high level of symptomatology or problems.
Timepoint [8] 0 0
Day 1 of each cycle up to data cut off 09 May 2017 (approximately 15 months)
Secondary outcome [9] 0 0
European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30) - EORTC-QLQ-LC30 is a 30-item cancer-specific questionnaire with multitrait scaling was used to create five functional domain scales: Physical, Role, Emotional, Social and Cognitive; two items evaluate global QoL; in addition, three symptom scales assess Fatigue, Pain and Emesis; and six single items assess other symptoms. The total score ranges from 0 to 100, with a high score for a functional scale representing a high/healthy level of functioning and a high score for a symptom scale or item representing a high level of symptomatology or problems.
Timepoint [9] 0 0
Day 1 of each cycle up to data cut off 09 May 2017 (approximately 15 months)
Secondary outcome [10] 0 0
EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) - The EQ-5D is a generic preference-based measure that indirectly measures the utility for health that generates an index-based summary score based upon societal preference weights. The EQ-5D-5L consists of 6 items that cover 5 main domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and a general visual analog scale (VAS) for health status. Each item has 5 response levels ranging from level 1 (no problem or none) to level 5 (unable to perform activity). The VAS ranges from 0 (worst health status) and 100 (best health status).
Timepoint [10] 0 0
Day 1 of each cycle up to data cut off 09 May 2017 (approximately 15 months)

Eligibility
Key inclusion criteria
- Subject agrees not to participate in another interventional study while on treatment.

- Female subject must either:

- Be of nonchildbearing potential: postmenopausal (defined as at least 1 year
without any menses) prior to Screening, or documented surgically sterile

- Or, if of childbearing potential: Agree not to try to become pregnant during the
study and for 28 days after the final study drug administration; And have a
negative serum pregnancy test at Screening; And, if heterosexually active, agree
to consistently use 2 forms of highly effective birth control (at least 1 of
which must be a highly effective method and one must be a barrier method)
starting at Screening and throughout the study period and for 28 days after the
final study drug administration.

- Female subject must not be breastfeeding at Screening or during the study period, and
for 28 days after the final study drug administration.

- Female subject must not donate ova starting at Screening and throughout the study
period, and for 28 days after the final study drug administration.

- Male subject and their female spouse/partners who are of childbearing potential must
be using highly effective contraception consisting of 2 forms of birth control (1 of
which must be a barrier method) starting at Screening and continue throughout the
study period and for 90 days after the final study drug administration.

- Male subject must not donate sperm starting at Screening and throughout the study
period and for 90 days after the final study drug administration.

- Subject has Eastern Cooperative Oncology Group (ECOG) performance status = 2.

- Subject has histologically confirmed locally advanced, metastatic or unresectable
Stage IIIB/IV adenocarcinoma NSCLC (newly diagnosed or recurrent). Subjects with mixed
histology are eligible if adenocarcinoma is the predominant histology.

- Subject has predicted life expectancy = 12 weeks in the opinion of the investigator.

- Subject must meet all of the following criteria on the laboratory tests that will be
analyzed centrally within 7 days prior to the first dose of study drug. In case of
multiple laboratory data within this period, the most recent data should be used.

- Neutrophil count > 1,000/mm3

- Platelet count = 7.5 x 104 /mm3

- Hemoglobin > 8.0 g/dL

- Serum creatinine ? 2.0 x upper limit of normal (ULN) or an estimated glomerular
filtration rate (eGFR) of > 50 mL/min as calculated by the Cockcroft Gault Method

- Total bilirubin ?1.5 x ULN (except for subjects with documented Gilbert's
syndrome)

- AST and ALT ? 3.0 x ULN or = 5 x ULN if subject has documented liver metastases

- Serum sodium level is = 130 mmol/L

- Subject has an EGFR activating mutation (exon 19 deletion or exon 21 L858R), with or
without T790M mutation, by local or central testing on examination of a NSCLC FFPE
specimen (archival or fresh biopsy). Subjects harboring both exon 19 deletion and exon
21 L858R mutations are not eligible. A tissue sample from the same block used to
determine eligibility by local testing should be available to send to the central lab
for confirmatory testing. Subjects randomized based on local results indicating
presence of EGFR mutation may remain on study if central results are discordant.

- Subject must have at least 1 measureable lesion based on RECIST V1.1. Previously
irradiated lesions will not be considered as measurable lesions.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Subject has received intervening anticancer treatment or previous treatment with
chemotherapy for metastatic disease other than palliative local radiation to painful
bone metastases completed at least 1 week prior to the first dose of study drug. The
administration of neoadjuvant or adjuvant chemotherapy is allowed as long as it has
finalized = 6 months before the first dose of study drug.

- Subject has received a prior treatment with a therapeutic agent targeting EGFR (e.g.,
afatinib, dacomitinib, ASP8273, etc).

- Subject has received investigational therapy within 28 days or 5 half-lives prior to
the first dose of study drug.

- Subject has received radiotherapy within 1 week prior to the first dose of study drug.
If the subject received radiotherapy > 1 week prior to study treatment, the irradiated
lesion cannot be the only lesion used for evaluating response.

- Subject has symptomatic central nervous system (CNS) metastasis. Subject with
previously treated brain or CNS metastases are eligible provided that the subject has
recovered from any acute effects of radiotherapy, does not have brain metastasis
related symptoms, is not requiring systemic steroids for at least 2 weeks prior to
study drug administration, and any whole brain radiation therapy was completed at
least 4 weeks prior to study drug administration, or any stereotactic radiosurgery
(SRS) was completed at least 2 weeks prior to study drug administration. Steroid
inhaler use or ointment treatment for other concomitant medical disease is permitted.

- Subject has received blood transfusions or hematopoietic factor therapy within 14 days
prior to the first dose of study drug.

- Subject has had a major surgical procedure (other than a biopsy) within 14 days prior
to the first dose of study drug, or one is planned during the course of the study.

- Subject has a known history of a positive test for human immunodeficiency virus (HIV)
infection.

- Subject has known history of serious hypersensitivity reaction to a known ingredient
of ASP8273, erlotinib or gefitinib.

- Subject has evidence of an active infection requiring systemic therapy within 14 days
prior to the planned first dose of study drug.

- Subject has severe or uncontrolled systemic diseases including uncontrolled
hypertension (blood pressure > 150/100 mmHg) or active bleeding diatheses.

- Subject has history of drug-induced interstitial lung disease (ILD) or any evidence of
active ILD.

- Subject has ongoing cardiac arrhythmia that is Grade = 2 or uncontrolled atrial
fibrillation of any grade.

- Subject currently has Class 3 or 4 New York Heart Association congestive heart
failure.

- Subject has history of severe/unstable angina, myocardial infarction or
cerebrovascular accident within 6 months prior to the planned first dose of study
drug.

- Subject has history of gastrointestinal ulcer or gastrointestinal bleeding within 3
months prior to the planned first dose of study drug.

- Subject has concurrent corneal disorder or any ophthalmologic condition which, in the
investigator's opinion, makes the subject unsuitable for study participation (i.e.,
advanced cataracts, glaucoma).

- Subject has difficulty taking oral medication or any digestive tract dysfunction or
inflammatory bowel disease that would interfere with the intestinal absorption of
drug.

- Subject has another past or active malignancy which requires treatment. Prior
carcinoma in situ or non-melanoma skin cancer after curative resection are permitted.

- Subject has any condition which, in the investigator's opinion, makes the subject
unsuitable for study participation.

- Subject has received potent CYP 3A4 inhibitors within 7 days prior to first dose of
study drug or proton pump inhibitors such as omeprazole within 14 days prior to first
dose of study drug.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 0 0
Site AU61003 - Randwick
Recruitment hospital [2] 0 0
Site AU61007 - Woolloongabba
Recruitment hospital [3] 0 0
Site AU61005 - Adelaide
Recruitment hospital [4] 0 0
Site AU61008 - East Melbourne
Recruitment hospital [5] 0 0
Site AU61002 - Fitzroy
Recruitment hospital [6] 0 0
Site AU61004 - Footscray
Recruitment postcode(s) [1] 0 0
2031 - Randwick
Recruitment postcode(s) [2] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
3002 - East Melbourne
Recruitment postcode(s) [5] 0 0
3065 - Fitzroy
Recruitment postcode(s) [6] 0 0
3011 - Footscray
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Louisiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Maine
Country [7] 0 0
United States of America
State/province [7] 0 0
Massachusetts
Country [8] 0 0
United States of America
State/province [8] 0 0
Minnesota
Country [9] 0 0
United States of America
State/province [9] 0 0
New Mexico
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
Pennsylvania
Country [12] 0 0
United States of America
State/province [12] 0 0
Tennessee
Country [13] 0 0
United States of America
State/province [13] 0 0
Washington
Country [14] 0 0
United States of America
State/province [14] 0 0
Wisconsin
Country [15] 0 0
Belgium
State/province [15] 0 0
West-Vlaanderen
Country [16] 0 0
Canada
State/province [16] 0 0
Ontario
Country [17] 0 0
Canada
State/province [17] 0 0
Quebec
Country [18] 0 0
Chile
State/province [18] 0 0
Región Metropolitana De Santia
Country [19] 0 0
Chile
State/province [19] 0 0
Valparaíso
Country [20] 0 0
France
State/province [20] 0 0
Gironde
Country [21] 0 0
France
State/province [21] 0 0
Hauts-de-Seine
Country [22] 0 0
France
State/province [22] 0 0
Ilej-de-France
Country [23] 0 0
France
State/province [23] 0 0
Indre-et-Loire
Country [24] 0 0
France
State/province [24] 0 0
Isère
Country [25] 0 0
France
State/province [25] 0 0
Loire
Country [26] 0 0
France
State/province [26] 0 0
Pyrénées-Atlantiques
Country [27] 0 0
France
State/province [27] 0 0
Rhône
Country [28] 0 0
Germany
State/province [28] 0 0
Baden-Württemberg
Country [29] 0 0
Germany
State/province [29] 0 0
Bayern
Country [30] 0 0
Germany
State/province [30] 0 0
Hessen
Country [31] 0 0
Germany
State/province [31] 0 0
Nordrhein-Westfalen
Country [32] 0 0
Hungary
State/province [32] 0 0
Fejér
Country [33] 0 0
Hungary
State/province [33] 0 0
Tatabánya
Country [34] 0 0
Hungary
State/province [34] 0 0
Vas
Country [35] 0 0
Hungary
State/province [35] 0 0
Veszprém
Country [36] 0 0
Hungary
State/province [36] 0 0
Budapest
Country [37] 0 0
Italy
State/province [37] 0 0
Lombardia
Country [38] 0 0
Italy
State/province [38] 0 0
Pordenone
Country [39] 0 0
Italy
State/province [39] 0 0
Bergamo
Country [40] 0 0
Italy
State/province [40] 0 0
Brescia
Country [41] 0 0
Italy
State/province [41] 0 0
Cremona
Country [42] 0 0
Italy
State/province [42] 0 0
Lucca
Country [43] 0 0
Italy
State/province [43] 0 0
Milano
Country [44] 0 0
Italy
State/province [44] 0 0
Piacenza
Country [45] 0 0
Italy
State/province [45] 0 0
Roma
Country [46] 0 0
Japan
State/province [46] 0 0
Ehime
Country [47] 0 0
Japan
State/province [47] 0 0
Hirosima [Hiroshima]
Country [48] 0 0
Japan
State/province [48] 0 0
Hokkaidô
Country [49] 0 0
Japan
State/province [49] 0 0
Hukuoka [Fukuoka]
Country [50] 0 0
Japan
State/province [50] 0 0
Hukuoka
Country [51] 0 0
Japan
State/province [51] 0 0
Hyogo
Country [52] 0 0
Japan
State/province [52] 0 0
Isikawa [Ishikawa]
Country [53] 0 0
Japan
State/province [53] 0 0
Kanagawa
Country [54] 0 0
Japan
State/province [54] 0 0
Miyagi
Country [55] 0 0
Japan
State/province [55] 0 0
Okayama
Country [56] 0 0
Japan
State/province [56] 0 0
Osaka
Country [57] 0 0
Japan
State/province [57] 0 0
Shizuoka
Country [58] 0 0
Japan
State/province [58] 0 0
Sizuoka [Shizuoka]
Country [59] 0 0
Japan
State/province [59] 0 0
Tôkyô [Tokyo]
Country [60] 0 0
Japan
State/province [60] 0 0
Niigata
Country [61] 0 0
Japan
State/province [61] 0 0
Wakayama
Country [62] 0 0
Japan
State/province [62] 0 0
Ôsaka [Osaka]
Country [63] 0 0
Korea, Republic of
State/province [63] 0 0
Chungcheongbugdo
Country [64] 0 0
Korea, Republic of
State/province [64] 0 0
Gyeonggi-do
Country [65] 0 0
Korea, Republic of
State/province [65] 0 0
Gyeonggido [Kyonggi-do]
Country [66] 0 0
Korea, Republic of
State/province [66] 0 0
Gyeonggido
Country [67] 0 0
Korea, Republic of
State/province [67] 0 0
Gyeongsangnamdo
Country [68] 0 0
Korea, Republic of
State/province [68] 0 0
Jeonrabugdo[Chollabuk-do]
Country [69] 0 0
Korea, Republic of
State/province [69] 0 0
Seoul Teugbyeolsi [Seoul-T'ukp]
Country [70] 0 0
Korea, Republic of
State/province [70] 0 0
Seoul Teugbyeolsi
Country [71] 0 0
Korea, Republic of
State/province [71] 0 0
Ulsan Gwang'yeogsi
Country [72] 0 0
Korea, Republic of
State/province [72] 0 0
Busan Gwang'yeogsi
Country [73] 0 0
Malaysia
State/province [73] 0 0
Pahang
Country [74] 0 0
Malaysia
State/province [74] 0 0
Pulau Pinang
Country [75] 0 0
Malaysia
State/province [75] 0 0
Sarawak
Country [76] 0 0
Netherlands
State/province [76] 0 0
Gelderland
Country [77] 0 0
Netherlands
State/province [77] 0 0
Noord-Holland
Country [78] 0 0
Peru
State/province [78] 0 0
Arequipa
Country [79] 0 0
Peru
State/province [79] 0 0
Lima
Country [80] 0 0
Portugal
State/province [80] 0 0
Lisboa
Country [81] 0 0
Portugal
State/province [81] 0 0
Coimbra
Country [82] 0 0
Romania
State/province [82] 0 0
Cluj
Country [83] 0 0
Romania
State/province [83] 0 0
Dolj
Country [84] 0 0
Romania
State/province [84] 0 0
Prahova
Country [85] 0 0
Romania
State/province [85] 0 0
Timis
Country [86] 0 0
Romania
State/province [86] 0 0
Bucuresti
Country [87] 0 0
Romania
State/province [87] 0 0
Sibiu
Country [88] 0 0
Russian Federation
State/province [88] 0 0
Arkhangel'skaya Oblast'
Country [89] 0 0
Russian Federation
State/province [89] 0 0
Bashkortostan
Country [90] 0 0
Russian Federation
State/province [90] 0 0
Chelyabinskaya Oblast'
Country [91] 0 0
Russian Federation
State/province [91] 0 0
Kabardino-Balkarskaya Respublika
Country [92] 0 0
Russian Federation
State/province [92] 0 0
Stavropol'skiy Kray
Country [93] 0 0
Russian Federation
State/province [93] 0 0
Saint Petersburg
Country [94] 0 0
Singapore
State/province [94] 0 0
Central Singapore
Country [95] 0 0
Spain
State/province [95] 0 0
Catalunya
Country [96] 0 0
Spain
State/province [96] 0 0
Guipúzcoa
Country [97] 0 0
Spain
State/province [97] 0 0
Málaga
Country [98] 0 0
Spain
State/province [98] 0 0
Madrid
Country [99] 0 0
Spain
State/province [99] 0 0
Ourense
Country [100] 0 0
Spain
State/province [100] 0 0
Sevilla
Country [101] 0 0
Spain
State/province [101] 0 0
Valencia
Country [102] 0 0
Taiwan
State/province [102] 0 0
Taichung
Country [103] 0 0
Taiwan
State/province [103] 0 0
Taoyuan
Country [104] 0 0
Taiwan
State/province [104] 0 0
Kaohsiung
Country [105] 0 0
Taiwan
State/province [105] 0 0
Tainan
Country [106] 0 0
Taiwan
State/province [106] 0 0
Taipei
Country [107] 0 0
Thailand
State/province [107] 0 0
Chiang Mai
Country [108] 0 0
Thailand
State/province [108] 0 0
Krung Thep Maha Nakhon [Bangkok]
Country [109] 0 0
Thailand
State/province [109] 0 0
Chiang Rai
Country [110] 0 0
Thailand
State/province [110] 0 0
Khon Kaen
Country [111] 0 0
Thailand
State/province [111] 0 0
Songkla
Country [112] 0 0
Ukraine
State/province [112] 0 0
Chernivets'ka Oblast'
Country [113] 0 0
Ukraine
State/province [113] 0 0
Dnipropetrovs'ka Oblast'
Country [114] 0 0
Ukraine
State/province [114] 0 0
Ivano-Frankivs'ka Oblast'
Country [115] 0 0
Ukraine
State/province [115] 0 0
L'vivs'ka Oblast'
Country [116] 0 0
Ukraine
State/province [116] 0 0
Volyns'ka Oblast'
Country [117] 0 0
Ukraine
State/province [117] 0 0
Zakarpats'ka Oblast'
Country [118] 0 0
United Kingdom
State/province [118] 0 0
Hertfordshire
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Wirral
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Sheffield

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Astellas Pharma Global Development, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the study was to evaluate the progression free survival (PFS), based on
independent radiologic review (IRR), of ASP8273 compared to erlotinib or gefitinib in
patients with locally advanced, metastatic or unresectable stage IIIB/IV adenocarcinoma
non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating
mutations.

This study also assessed Overall survival (OS); Overall response rate (ORR) as assessed by
IRR; PFS as assessed by the investigator; Disease control rate (DCR) as assessed by IRR;
Duration of Response (DOR) by IRR; Safety of ASP8273; and Quality of Life (QOL) and
patient-reported outcome (PRO) parameters.
Trial website
https://clinicaltrials.gov/show/NCT02588261
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Monitor
Address 0 0
Astellas Pharma Global Development, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT02588261